Angelo Avogaro

Angelo Avogaro

Via Giustiniani 2
Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 367 publications

Response to Lu Li and colleagues.

Response to Lu Li and colleagues.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: August 02, 2026

Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D.

Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D.

Journal: Journal of endocrinological investigation

Published: June 12, 2026

DPP-4 inhibitors in current diabetes care: their foundational role in treating to target.

DPP-4 inhibitors in current diabetes care: their foundational role in treating to target.

Journal: Diabetes research and clinical practice

Published: March 13, 2026

Discontinuation of incretin-based therapies in obesity: the complexity of a breakup.

Discontinuation of incretin-based therapies in obesity: the complexity of a breakup.

Journal: European journal of internal medicine

Published: March 05, 2026

The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.

The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.

Journal: Cardiovascular diabetology

Published: February 02, 2026

Implementing sodium-glucose co-transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome: a multidisciplinary expert perspective.

Implementing sodium-glucose co-transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome: a multidisciplinary expert perspective.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: February 02, 2026

Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.

Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.

Journal: European journal of clinical investigation

Published: December 12, 2025

The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.

The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.

Journal: Acta diabetologica

Published: December 05, 2025

Revisiting the burden and patterns of myocardial infarction in type 1 diabetes.

Revisiting the burden and patterns of myocardial infarction in type 1 diabetes.

Journal: The lancet. Diabetes & endocrinology

Published: November 30, 2025

Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.

Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.

Journal: Diabetes, obesity & metabolism

Published: July 22, 2025

Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.

Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.

Journal: The Lancet regional health. Europe

Published: July 11, 2025

Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods.

Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods.

Journal: Cardiovascular diabetology

Published: July 02, 2025

Showing 1-12 of 367

Last Updated: 09/26/2026